VeriStrat utilizes mass spectrometry to evaluate tumor EGFR ligand levels and predict patient response and survival outcome to erlotinib and other EGFR inhibitors from serum samples [34], [35], [36]. This evidence concerns the gene EGFR and neoplasm.